Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata

Journal of Experimental Therapeutics and Oncology

Volumn 3, Issue 3, 2003, Pages 147-158

  Rajagopal, Sriram ^a   Kumar, R Ajaya ^a   Deevi, Dhanvanthri S ^a   Satyanarayana, Chitkala ^a   Rajagopalan, R ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Andrographolide; Anticancer drugs; Cell cycle; Cytokine; Immunostimulation

Indexed keywords

ANDROGRAPHOLIDE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 4; DITERPENE; INTERLEUKIN 2; PLANT EXTRACT; PROTEIN P27; TUMOR NECROSIS FACTOR ALPHA;

ANDROGRAPHIS; ANDROGRAPHIS PANICULATA; ANIMAL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOSYNTHESIS; CANCER CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN HT29; CELL TYPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG ISOLATION; DRUG POTENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MEDICINAL PLANT; MELANOMA CELL; METABOLISM; MOUSE; NONHUMAN; PHARMACOPHORE; PHYTOTHERAPY; PRIORITY JOURNAL; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANDROGRAPHIS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DITERPENES; FLOW CYTOMETRY; HT29 CELLS; HUMANS; INTERLEUKIN-2; LYMPHOCYTES; MICE; PHYTOTHERAPY; PLANT EXTRACTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0141457852     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1359-4117.2003.01090.x     Document Type: Article

References (42)

1. Wang HK. The therapeutic potential of flavonoids. Expert Opin Investig Drugs 9(9): 2103-2119, 2000.
2. Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Multi-functional aspects of the action of indole-3-carbinol as an antitumor agent. Ann N Y Acad Sci 889: 204-213, 1999.
3. Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des 8(19): 1695-1706, 2002.
4. Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci 957: 210-229, 2002.
5. Fujiki H, Suganuma M, Imai K, Nakachi K. Green tea: cancer preventive beverage and and/or drug. Cancer Lett 188(1-2): 9-13, 2002.
6. Siripong P, Konckathip B, Preechanukool K, Picha P, Tunsuwan K, Taylor WC. Cytotoxic diterpenoid constituents from Andrographis paniculata nees leaves. J Sci Soc Thai 18: 187-194, 1992.
7. Shen YC, Chen CF, Chiou WF. Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. Br J Pharmacol 35(2): 399-406, 2002.
8. Puri A, Saxena R, Saxena RP, Saxena KC, Srivastava V, Tandon JS. Immunostimulant agents from Andrographis paniculata. J Nat Prod 56(7): 995-999, 1993.
9. Zhao HY, Fang WY. Antithrombotic effects of Andrographis paniculata nees in preventing myocardial infarction. Chin Med J (Engl) 104(9): 770-775, 1991.
10. Mehrotra R, Rawat S, Kulshreshtha DK, Patnaik GK, Dhawan BN. In vitro studies on the effect of certain natural products against hepatitis B virus. Indian J Med Res 92: 133-138, 1990.
11. Basak A, Cooper S, Roberge AG, Banik UK, Chretien M, Seidah NG. Inhibition of proprotein convertases-1, -7 and furin by diterpines of Andrographis paniculata and their succinoyl esters. Biochem J 338(Pt 1): 107-113, 1999.
12. Zhang XF, Tan BK. Antihyperglycaemic and anti-oxidant properties of Andrographis paniculata in normal and diabetic rats. Clin Exp Pharmacol Physiol 27(5-6): 358-363, 2000.
13. Zhang CY, Tan BK. Hypotensive activity of aqueous extract of Andrographis paniculata in rats. Clin Exp Pharmacol Physiol 23(8): 675-678, 1996.
14. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ Jr, Rollins BJ. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7(6): 1590-1599, 2001.
15. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM. Homoharringtonine: history, current research, and future direction. Cancer 92(6): 1591-1605, 2001.
16. Matsuda T, Kuroyanagi M, Sugiyama S, Umehara K, Ueno A, Nishi K. Cell differentiation-inducing diterpenes from Andrographis paniculata nees. Chem Pharm Bull (Tokyo) 42(6): 1216-1225, 1994.
17. Huang LW, Chao SL, Hwang JL, Chou YY. Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecol Oncol 85(3): 524-528, 2002.
18. Katner AL, Hoang QB, Gootam P, Jaruga E, Ma Q, Gnarra J, Rayford W. Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1). Prostate 53(1): 77-87, 2002.
19. Takeuchi S, Okumura T, Motomura W, Nagamine M, Takahashi N, Kohgo Y. Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells. Jpn J Cancer Res 93(7): 774-782, 2002.
20. Patel V, Lahusen T, Leethanakul C, et al. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). Clin Cancer Res 8(11): 3549-3560, 2002.
21. Zi X, Grasso AW, Kung H, et al. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 58: 1920-1929, 1998.
22. Zi X, Agarwal, R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem Biophys Res Commun 263: 528-536, 1999.
23. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56(13): 2973-2978, 1996.
24. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate 46: 98-107, 2001.
25. Ahmad N, Cheng P, Mukhtar H. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem Biophys Res Commun 275: 328-334, 2000.
26. Agarwal C, Sharma Y, Agarwal R. Anticarcinogenic effect of a polyphenolic fraction isolated from grape seeds in human prostate carcinoma DU145 cells: modulation of mitogenic signaling and cell cycle regulators and induction of G1 arrest and apoptosis. Mol Carcinog 28: 129-138, 2000.
27. Katdare M, Osborne MP, Telang NT. Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals. Oncol Rep 5: 311-315, 1998.
28. Bai F, Matsui T, Ohtani-Fujita N, et al. Promoter activation and following induction of the p21/waf1 gene by flavone is involved in G1 phase arrest in A549 lung adenocarcinoma cells. FEBS Lett 437: 61-64, 1998.
29. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815, 2001.
30. Campling BG, el-Deiry WS. Clinical implications of p53 mutations in lung cancer. Methods Mol Med 75: 53-77, 2003.
31. Ferreira CG, Tolis C, Giaccone G. p53 and chemosensitivity. Ann Oncol 10: 1011-1021, 1999.
32. Calabrese C, Berman SH, Babish JG, et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother Res 14(5): 333-338, 2000.
33. Baselmans AH, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 51(9): 492-498, 2002.
34. See D, Mason S, Roshan R. Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunol Invest 31(2): 137-153, 2002.
35. Parmiani G, Rivoltini L, Andreola G, Carrabba M. Cytokines in cancer therapy. Immunol Lett 74: 41-44, 2000.
36. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M. Tumor-induced immune dysfunction. Cancer Immunol Immunother 48: 353-362, 1999.
37. Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal, and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61: 765-772, 1995.
38. Lamm DL, Riggs DR. Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. J Nutr 131(3s): 1067S-1070S, 2001.
39. Stein GM, Berg PA. Modulation of cellular and humoral immune responses during exposure of healthy individuals to an aqueous mistletoe extract. Eur J Med Res 3(6): 307-14, 1998.
40. Lee YS, Chung IS, Lee IR, Kim KH, Hong WS, Yun YS. Activation of multiple effector pathways of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from Panax ginseng. Anticancer Res 17(1A): 323-31, 1997.
41. Lersch C, Zeuner M, Bauer A, et al. Stimulation of the immune response in outpatients with hepatocellular carcinomas by low doses of cyclophosphamide (LDCY), echinacea purpurea extracts (Echinacin) and thymostimulin. Arch Geschwulstforsch 60(5): 379-83, 1990.
42. Zagozdzon R, Golab J. Immunomodulation by anticancer chemotherapy: more is not always better. Int J Oncol 18(2): 417-24, 2001.